Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,838,048
  • Shares Outstanding, K 2,533,280
  • Annual Sales, $ 48,704 M
  • Annual Income, $ 13,049 M
  • 60-Month Beta 0.33
  • Price/Sales 4.55
  • Price/Cash Flow 11.96
  • Price/Book 5.11
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 27.74% ( +0.37%)
  • Historical Volatility 18.96%
  • IV Percentile 95%
  • IV Rank 54.28%
  • IV High 34.71% on 11/30/21
  • IV Low 19.45% on 03/25/22
  • Put/Call Vol Ratio 0.67
  • Today's Volume 20,476
  • Volume Avg (30-Day) 20,304
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 595,828
  • Open Int (30-Day) 578,772

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 1.74
  • Number of Estimates 7
  • High Estimate 1.94
  • Low Estimate 1.62
  • Prior Year 1.75
  • Growth Rate Est. (year over year) -0.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.52 +1.96%
on 09/21/22
89.17 -3.35%
on 09/12/22
-3.08 (-3.45%)
since 08/26/22
3-Month
84.52 +1.96%
on 09/21/22
95.72 -9.97%
on 06/27/22
-6.95 (-7.46%)
since 06/24/22
52-Week
71.50 +20.53%
on 12/07/21
95.72 -9.97%
on 06/27/22
+12.57 (+17.08%)
since 09/24/21

Most Recent Stories

More News
Dow Jones ETF Avoids Bear Market: 4 Stocks in Green

Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.

CVX : 140.96 (-2.63%)
UNH : 508.36 (-1.02%)
MRK : 86.18 (-0.69%)
AMGN : 226.87 (-0.04%)
DIA : 292.72 (-1.06%)
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris

Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in...

MRK : 86.18 (-0.69%)
AGEN : 1.96 (-7.98%)
MORF : 25.24 (-2.85%)
VTRS : 8.53 (-1.84%)
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.

AZN : 53.02 (-2.86%)
GSK : 28.82 (-1.84%)
RHHBY : 38.6900 (-2.30%)
MRK : 86.18 (-0.69%)
LLY : 307.50 (-1.27%)
My Take: 4 Strong Growth Stocks to Buy This Week

Quality and resiliency shine through when trouble starts setting in.

AAPL : 150.77 (+0.23%)
QCOM : 119.74 (-1.20%)
NVDA : 122.28 (-2.30%)
TSM : 73.01 (-1.16%)
MRK : 86.18 (-0.69%)
AMZN : 115.15 (+1.20%)
GPC : 149.13 (-1.26%)
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

MRK : 86.18 (-0.69%)
APTO : 0.5425 (-9.51%)
ORIC : 3.15 (-7.35%)
EVAX : 2.75 (-5.50%)
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

MRK : 86.18 (-0.69%)
Merck Animal Health to Acquire Vence

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that it has signed a definitive agreement...

MRK : 86.18 (-0.69%)
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved in China as first-line maintenance treatment for adult patients...

MRK : 86.18 (-0.69%)
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent...

MRK : 86.18 (-0.69%)
3 No-Brainer Stocks to Buy if You Have Money to Spend

Raging inflation and the Fed’s commitment to bring it under control with rate hikes are raising recession worries. However, according to BofA, the market could see a rally later this year. Given the...

APA : 31.84 (-3.13%)
MRK : 86.18 (-0.69%)
MSFT : 237.45 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 88.25
2nd Resistance Point 87.48
1st Resistance Point 86.83
Last Price 86.18
1st Support Level 85.41
2nd Support Level 84.64
3rd Support Level 83.99

See More

52-Week High 95.72
Fibonacci 61.8% 86.47
Last Price 86.18
Fibonacci 50% 83.61
Fibonacci 38.2% 80.75
52-Week Low 71.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar